J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug·Investor's Business Daily

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.

Advertisement